The future of medical device innovation currently hangs on a series of closed-door discussions that will determine how billions of dollars are allocated to the Food and Drug Administration over the coming years. These high-stakes negotiations for the sixth iteration of the Medical Device User Fee
James Maitland is a leading expert in the intersection of healthcare operations and pharmaceutical regulation, specializing in the nuances of the 340B Drug Pricing Program. With years of experience advising safety-net providers on compliance and technological integration, he has become a vocal
Strengthening Executive Oversight for a New Era of Public Health The strategic realignment recently enacted within the Department of Health and Human Services (HHS) marks a pivotal moment in the administration’s efforts to reshape American healthcare. By promoting four high-level officials into
The historical struggle to move patient records between competing hospital systems has long been a primary obstacle to delivering efficient medical care across the United States, yet the landscape in 2026 reflects a transformative shift toward seamless data mobility. Federal officials from the
The American healthcare landscape is currently witnessing a seismic shift as the Federal Trade Commission (FTC) nears a comprehensive resolution with the nation’s dominant pharmacy benefit managers (PBMs). At the heart of this movement is a concerted effort to dismantle pricing structures that have
The traditional landscape of American healthcare is undergoing a profound structural realignment as federal payers move away from the polite invitation of voluntary participation toward the firm requirement of mandatory risk. For over a decade, the Centers for Medicare & Medicaid Services (CMS)
